Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Taking artemisinin-piperaquine
Control group:Symptomatic treatment with non-antiviral drugs
Sponsors
Hongqi Hospital Affiliated to Mudangjiang Medical University
Eligibility
Sex/Gender
All
Age
2 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 2 to 65 years old, and signed informed consent; 2. According to the diagnostic criteria of the "New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7)" issued by the National Health and Health Commission, those who have been diagnosed with CoVID-19 of light and common type and have been treated with hydroxychloroquine and Abidol but nCoV Nucleic acid did not turn negative. The specific diagnostic criteria are as follows: (1) light type: The clinical symptoms are mild, and there is no pneumonia manifestation in imaging; (2) Common type: It has fever, respiratory tract and other symptoms. Pneumonia can be seen on imaging; (3) The patient who have been diagnosed with CoVID-19 of light and common type and have been treated with hydroxychloroquine and Abidol but nCoV Nucleic acid did not turn negative.
Exclusion criteria
Exclusion criteria: 1. Pregnant women within 3 months of pregnancy; 2. Patients with liver and kidney disease and those with liver and kidney injury 3. Patients with blood diseases (such as leukopenia, thrombocytopenia, etc.). 4. Electrocardiogram prompting patients with severely extended QT.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerance;Viral load of nCoV;Blood routine;Immunological examination;Blood liver and kidney function test;Myocardial enzyme biochemical examination;ECG examination;Urine routine;body temperature;pulse;Breathe;blood pressure;CT examination of the lungs; | — |
Countries
China
Contacts
Public ContactFengjie Xie
Hongqi Hospital Affiliated to Mudangjiang Medical University
Outcome results
None listed